Drug approval overregulation
Article Abstract:
Political pressures on the Food and Drug Administration (FDA) have resulted in its maintaining higher than optimal drug approval standards that are becoming detrimental to consumers. In its desire to avoid the costs of approving a nonbeneficial and possibly harmful drug, the FDA fails to consider the consequences of delaying the approval of a potentially beneficial drug. Current drug approval reform proposals include accelerated approval of drugs for life-threatening diseases, decreasing drug development time, reinterpretaion of the efficacy standard and limiting the FDA's authority.
Publication Name: Regulation
Subject: Law
ISSN: 0147-0590
Year: 1992
User Contributions:
Comment about this article or add new information about this topic:
Regulatory report card
Article Abstract:
The Republicans in Congress have failed to pass most of the promised deregulation measures contained under the Contract With America. With the exception of the accountability for unfunded mandates measure, Congress has not yet approved the bills on the protection of property rights, regulatory budgeting, federal regulatory abuse protection and cost-benefit analysis/risk assessment. Reform bills on the Clean Air Act, Safe Drinking Water Act, Superfund, Americans with Disabilities Act and the Community Reinvestment Act were also stalled.
Publication Name: Regulation
Subject: Law
ISSN: 0147-0590
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Continuing legal education. part 6
- Abstracts: "Continuous" regulatory reform at the Federal Trade Commission. How changes in the Federal Register can help improve regulatory accountability
- Abstracts: The benefits of branching deregulation. The new safety net
- Abstracts: Distorting 'equal opportunity'. Politics or sound policy